The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of hiv-infected patients

Deborah L. Birx, John Brundage, Kristin Larson, Renata Engler, Laurie Smith, Edward Squire, Gary Carpenter, Michael Sullivan, Joanne Rhoads, Charles Oster, William James, George Lupton, Thomas Wierzba, Donald Burke, Robert Redfield

Research output: Contribution to journalArticle

Abstract

Many reagents and techniques have been used for delayed-type hypersensitivity (DTH) skin testing in the evaluation of HIV-infected patients, resulting in varied interpretation of the utility of DTH skin testing in this population. We report the development of a simple algorithm for selection of DTH antigens and the clinical relevance of DTH skin testing in HIV disease. Antigens and concentrations for testing were first evaluated in a demographi- cally matched, HIV-negative, immunologically healthy population. The testing scheme was then applied to the HIV population of interest for 5 years at several clinical sites. The antigens and concentrations selected resulted in 100% reactivity to two or more antigens in the HIV-negative cohort. Anergy is thus a distinct immunologic abnormality. Although some correlation (r2 = 0.6) of skin test reactivity and CD4 cell count was found in a cohort of HIV-infected individuals, anergy was found to be independently predictive of the development of symptomatic late-stage disease (Walter Reed Stage 6), AIDS, or death. This stepwise evaluation of skin testing and reagents has led to the modification of the skin testing protocol by defining the minimum number of antigens required and establishing the independent prognostic role of DTH skin testing in the evaluation of HIV-infected patients. The addition of mumps (40 CFU/ ml), tetanus (1:10), and Candida (1:10) to the purified protein derivative (PPD) skin test provides the critical controls to evaluate the status of PPD skin test in HIV-infected individuals as well as to provide a useful and prognostic clinical immunology evaluation.

Original languageEnglish (US)
Pages (from-to)1248-1257
Number of pages10
JournalJournal of Acquired Immune Deficiency Syndromes
Volume6
Issue number11
StatePublished - 1993
Externally publishedYes

Fingerprint

Delayed Hypersensitivity
HIV
Skin
Skin Tests
Antigens
HIV Antigens
Population
Mumps
Tetanus
CD4 Lymphocyte Count
Allergy and Immunology
Candida
Acquired Immunodeficiency Syndrome
Proteins

Keywords

  • Anergy
  • Delayed-type hypersensitivity skin testing
  • Hiv disease
  • Prognosis

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Virology
  • Immunology and Allergy

Cite this

Birx, D. L., Brundage, J., Larson, K., Engler, R., Smith, L., Squire, E., ... Redfield, R. (1993). The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of hiv-infected patients. Journal of Acquired Immune Deficiency Syndromes, 6(11), 1248-1257.

The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of hiv-infected patients. / Birx, Deborah L.; Brundage, John; Larson, Kristin; Engler, Renata; Smith, Laurie; Squire, Edward; Carpenter, Gary; Sullivan, Michael; Rhoads, Joanne; Oster, Charles; James, William; Lupton, George; Wierzba, Thomas; Burke, Donald; Redfield, Robert.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 6, No. 11, 1993, p. 1248-1257.

Research output: Contribution to journalArticle

Birx, DL, Brundage, J, Larson, K, Engler, R, Smith, L, Squire, E, Carpenter, G, Sullivan, M, Rhoads, J, Oster, C, James, W, Lupton, G, Wierzba, T, Burke, D & Redfield, R 1993, 'The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of hiv-infected patients', Journal of Acquired Immune Deficiency Syndromes, vol. 6, no. 11, pp. 1248-1257.
Birx, Deborah L. ; Brundage, John ; Larson, Kristin ; Engler, Renata ; Smith, Laurie ; Squire, Edward ; Carpenter, Gary ; Sullivan, Michael ; Rhoads, Joanne ; Oster, Charles ; James, William ; Lupton, George ; Wierzba, Thomas ; Burke, Donald ; Redfield, Robert. / The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of hiv-infected patients. In: Journal of Acquired Immune Deficiency Syndromes. 1993 ; Vol. 6, No. 11. pp. 1248-1257.
@article{97a0fd411dc2426aab7a54031d89a64a,
title = "The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of hiv-infected patients",
abstract = "Many reagents and techniques have been used for delayed-type hypersensitivity (DTH) skin testing in the evaluation of HIV-infected patients, resulting in varied interpretation of the utility of DTH skin testing in this population. We report the development of a simple algorithm for selection of DTH antigens and the clinical relevance of DTH skin testing in HIV disease. Antigens and concentrations for testing were first evaluated in a demographi- cally matched, HIV-negative, immunologically healthy population. The testing scheme was then applied to the HIV population of interest for 5 years at several clinical sites. The antigens and concentrations selected resulted in 100{\%} reactivity to two or more antigens in the HIV-negative cohort. Anergy is thus a distinct immunologic abnormality. Although some correlation (r2 = 0.6) of skin test reactivity and CD4 cell count was found in a cohort of HIV-infected individuals, anergy was found to be independently predictive of the development of symptomatic late-stage disease (Walter Reed Stage 6), AIDS, or death. This stepwise evaluation of skin testing and reagents has led to the modification of the skin testing protocol by defining the minimum number of antigens required and establishing the independent prognostic role of DTH skin testing in the evaluation of HIV-infected patients. The addition of mumps (40 CFU/ ml), tetanus (1:10), and Candida (1:10) to the purified protein derivative (PPD) skin test provides the critical controls to evaluate the status of PPD skin test in HIV-infected individuals as well as to provide a useful and prognostic clinical immunology evaluation.",
keywords = "Anergy, Delayed-type hypersensitivity skin testing, Hiv disease, Prognosis",
author = "Birx, {Deborah L.} and John Brundage and Kristin Larson and Renata Engler and Laurie Smith and Edward Squire and Gary Carpenter and Michael Sullivan and Joanne Rhoads and Charles Oster and William James and George Lupton and Thomas Wierzba and Donald Burke and Robert Redfield",
year = "1993",
language = "English (US)",
volume = "6",
pages = "1248--1257",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of hiv-infected patients

AU - Birx, Deborah L.

AU - Brundage, John

AU - Larson, Kristin

AU - Engler, Renata

AU - Smith, Laurie

AU - Squire, Edward

AU - Carpenter, Gary

AU - Sullivan, Michael

AU - Rhoads, Joanne

AU - Oster, Charles

AU - James, William

AU - Lupton, George

AU - Wierzba, Thomas

AU - Burke, Donald

AU - Redfield, Robert

PY - 1993

Y1 - 1993

N2 - Many reagents and techniques have been used for delayed-type hypersensitivity (DTH) skin testing in the evaluation of HIV-infected patients, resulting in varied interpretation of the utility of DTH skin testing in this population. We report the development of a simple algorithm for selection of DTH antigens and the clinical relevance of DTH skin testing in HIV disease. Antigens and concentrations for testing were first evaluated in a demographi- cally matched, HIV-negative, immunologically healthy population. The testing scheme was then applied to the HIV population of interest for 5 years at several clinical sites. The antigens and concentrations selected resulted in 100% reactivity to two or more antigens in the HIV-negative cohort. Anergy is thus a distinct immunologic abnormality. Although some correlation (r2 = 0.6) of skin test reactivity and CD4 cell count was found in a cohort of HIV-infected individuals, anergy was found to be independently predictive of the development of symptomatic late-stage disease (Walter Reed Stage 6), AIDS, or death. This stepwise evaluation of skin testing and reagents has led to the modification of the skin testing protocol by defining the minimum number of antigens required and establishing the independent prognostic role of DTH skin testing in the evaluation of HIV-infected patients. The addition of mumps (40 CFU/ ml), tetanus (1:10), and Candida (1:10) to the purified protein derivative (PPD) skin test provides the critical controls to evaluate the status of PPD skin test in HIV-infected individuals as well as to provide a useful and prognostic clinical immunology evaluation.

AB - Many reagents and techniques have been used for delayed-type hypersensitivity (DTH) skin testing in the evaluation of HIV-infected patients, resulting in varied interpretation of the utility of DTH skin testing in this population. We report the development of a simple algorithm for selection of DTH antigens and the clinical relevance of DTH skin testing in HIV disease. Antigens and concentrations for testing were first evaluated in a demographi- cally matched, HIV-negative, immunologically healthy population. The testing scheme was then applied to the HIV population of interest for 5 years at several clinical sites. The antigens and concentrations selected resulted in 100% reactivity to two or more antigens in the HIV-negative cohort. Anergy is thus a distinct immunologic abnormality. Although some correlation (r2 = 0.6) of skin test reactivity and CD4 cell count was found in a cohort of HIV-infected individuals, anergy was found to be independently predictive of the development of symptomatic late-stage disease (Walter Reed Stage 6), AIDS, or death. This stepwise evaluation of skin testing and reagents has led to the modification of the skin testing protocol by defining the minimum number of antigens required and establishing the independent prognostic role of DTH skin testing in the evaluation of HIV-infected patients. The addition of mumps (40 CFU/ ml), tetanus (1:10), and Candida (1:10) to the purified protein derivative (PPD) skin test provides the critical controls to evaluate the status of PPD skin test in HIV-infected individuals as well as to provide a useful and prognostic clinical immunology evaluation.

KW - Anergy

KW - Delayed-type hypersensitivity skin testing

KW - Hiv disease

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0027361830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027361830&partnerID=8YFLogxK

M3 - Article

C2 - 7901383

AN - SCOPUS:0027361830

VL - 6

SP - 1248

EP - 1257

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 11

ER -